摘要
目的探讨改良根治术后的乳腺癌免疫组化各分子亚型的预后特性和年复发变化。方法回顾性分析2003年1月至2008年8月常州市第一人民医院应用改良根治术治疗310例乳腺癌的临床资料。根据免疫组化雌激素受体(ER)、孕激素受体(PR)和人类表皮生长因子受体2(HER2)的检测结果分为luminal型、HER2阳性型、三阴性乳腺癌,对比分析不同亚型乳腺癌的临床复发风险。结果 310例乳腺癌总体年复发风险高峰在2年左右,5年有一个平稳的小高峰。免疫组化各分子亚型HER2阳性年复发风险最高,三阴性乳腺癌次之,Luminal型复发风险最低(P<0.05)。HER2阳性型年复发风险最高,但是复发高峰在2～3年,之后直线下降;三阴性乳腺癌复发高峰虽然较HER2阳性型低,但是维持在2～5年复发,延时较长。结论免疫组化的各分子亚型对乳腺癌临床复发起不同的预后指导作用。
Objective To analyze the prognosis feature and annual recurrence risk for breast cancer patients classified by immunohistochemistry molecular subtypes after radical mastectomy. Methods The clinical data of 310 cases of female unilateral breast cancer performed modified radical mastectomy between January 2003 and August 2008 in the First People＇s Hospital of Changzhou were analyzed retrospectively. All the cases were classified as luminal, HER2＋ and triple negative subtypes according to their immunohistochemistry resuhs of ER, PR and HER2. Survival curves were performed with Kaplan-Meier method and annual recurrence hazard was estimated by hazard function. Results Annual recurrence hazard curve for entire population showed a double-peaked pattern, with a first major recurrence surge reaching the maximum at the second year after surgery and a second low recurrence peak near the 5th year. Compared with.luminal subtype, HER＋ subtype had a much higher annual recurrence peak. The annual recurrence peak of triple negative subtype breast cancer, though lower than HER2＋ subtype, was still higher than luminal subtype. The peak of HER2 ＋ subtype decreased vastly after 2-3 years. Triple negative subtype had a relative stable peak from 2-5 year. Conclusion The annual recurrence features of breast cancer subtypes can provide different guidance for prognosis.
出处
《中国实用外科杂志》
CSCD
北大核心
2012年第11期938-941,共4页
Chinese Journal of Practical Surgery
关键词
乳腺癌
免疫组化分子
亚型
breast cancer
immunohistochemistry
subtype
